GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: June 27, 2003, 17:57:14 ; Search time 37 Seconds
(without alignments)
54.021 Million cell updates/sec

Title: US-09-300-612-1
Perfect score: 84
Sequence: 1 LKAMDPTPPLWIKTE 15

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	84	100.0	15	18	AAW11575	N-terminal peptide
2	84	100.0	15	19	AAW53841	N-terminus of opos
3	54	64.3	10	19	AAW53843	N-terminus of opos
4	47	56.0	303	22	ABG18144	Novel human diagno
5	46	54.8	267	21	AAY74718	Neisseria meningit
6	46	54.8	267	21	AAY74721	Neisseria meningit
7	46	54.8	729	22	ABB59797	Drosophila melanog
8	46	54.8	1189	15	AAR56496	TATA-binding prote
9	46	54.8	1213	17	AAW06086	Drosophila TATA-bi
10	46	54.8	1213	18	AAW25029	TATA-binding prote
11	46	54.8	1219	22	ABB62618	Drosophila melanog
12	45	53.6	267	21	AAY74720	Neisseria meningit
13	44	52.4	37	22	ABB42105	Peptide #9611 enco
14	44	52.4	37	22	AAM62985	Human brain expres
15	44	52.4	37	22	AAM75798	Human bone marrow
16	44	52.4	76	21	AAG54516	Zea mays protein f
17	44	52.4	79	21	AAG54515	Zea mays protein f
18	44	52.4	92	21	AAG54605	Zea mays protein f
19	44	52.4	95	21	AAG54604	Zea mays protein f
20	44	52.4	120	22	AAO10737	Human polypeptide
21	44	52.4	125	22	AAB93318	Human protein sequ
22	44	52.4	156	22	ABG22890	Novel human diagno
23	44	52.4	1457	22	AAU32796	Novel human secret
24	43	51.2	316	22	ABG23871	Novel human diagno
25	43	51.2	393	22	AAM79784	Human protein SEQ
26	43	51.2	496	21	AAG27883	Arabidopsis thalia
27	43	51.2	522	21	AAG27882	Arabidopsis thalia
28	43	51.2	687	21	AAG27881	Arabidopsis thalia
29	42	50.0	94	22	AAO02179	Human polypeptide
30	42	50.0	108	22	AAU53021	Propionibacterium
31	42	50.0	345	22	AAB94009	Human protein sequ
32	42	50.0	410	21	AAG12869	Arabidopsis thalia
33	42	50.0	410	21	AAG43050	Arabidopsis thalia
34	42	50.0	410	21	AAG50737	Arabidopsis thalia
35	42	50.0	419	21	AAG50729	Arabidopsis thalia
36	42	50.0	449	21	AAG12868	Arabidopsis thalia
37	42	50.0	449	21	AAG43049	Arabidopsis thalia
38	42	50.0	449	21	AAG50736	Arabidopsis thalia
39	42	50.0	453	21	AAG12867	Arabidopsis thalia
40	42	50.0	453	21	AAG43048	Arabidopsis thalia
41	42	50.0	453	21	AAG50735	Arabidopsis thalia
42	42	50.0	458	21	AAG50728	Arabidopsis thalia
43	42	50.0	462	21	AAG50727	Arabidopsis thalia
44	42	50.0	578	22	AAM93461	Human polypeptide,
45	42	50.0	580	22	AAB20447	Human seizure rela

ALIGNMENTS

RESULT 1
AAW11575
ID AAW11575 standard; peptide; 15 AA.
XX
AC AAW11575;
XX
DT 20-MAR-1997 (first entry)
XX
DE N-terminal peptide from lethal toxin neutralising factor.
XX
KW Lethal toxin neutralising factor; LTNF; opossum; bee toxin;
KW scorpion toxin; plant toxin; bacterial toxin; venom; sting;
KW snake bite.
XX
OS Didelphis virginiana.
XX
PN US5576297-A.
XX
PD 19-NOV-1996.
XX
PF 10-MAY-1993; 93US-0058387.
XX
PR 22-SEP-1994; 94US-0310340.
PR 10-MAY-1993; 93US-0058387.
XX
PA (LIPP/) LIPPS B V.
PA (LIPP/) LIPPS F W.
XX
PI Lipps BV, Lipps FW;
XX
DR WPI; 1997-011287/01.
XX
PT Treatment of victims of bee or scorpion stings or plant or bacterial

PT toxins - by admin. of lethal toxin-neutralising factor or its
PT N-terminal peptide
XX
PS Claim 7; Column 9; 9pp; English.
XX
CC The present sequence is from the N-terminus of a 68 kD protein
CC purified from the serum of the opossum Didelphis virginiana. The
CC full-length protein is a lethal toxin neutralising factor (LTNF).
CC The use of purified LTNF or of the chemically synthesised 15mer
CC N-terminal peptide for treating victims of bee stings, scorpion
CC stings and bacterial or plant toxins is claimed. The patent
CC disclosure does not provide any evidence for neutralising activity
CC against these various toxins. There is evidence of significant
CC neutralising activity of the opossum LTNF and the 15mer peptide
CC against venom from snakes of the families Crotalidae, Elaphidae,
CC Hydrolidae and Viperidae.
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 84; DB 18; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.7e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKAMDPTPPLWIKTE 15
||||||||||||||||
Db 1 LKAMDPTPPLWIKTE 15

RESULT 2
AAW53841
ID AAW53841 standard; peptide; 15 AA.
XX
AC AAW53841;
XX
DT 08-JUL-1998 (first entry)
XX
DE N-terminus of opossum LTNF.
XX
KW LTNF; lethal toxin neutralising factor; opossum; envenomation; therapy;
KW anti-haemorrhagic protein; Elapidae; Viperidae; sea snake; snake bite;
KW sepsis; allergy; bee sting; scorpion sting; plant toxin; bacterial toxin;
KW histamine reaction treatment.
XX
OS Didelphis virginiana.
XX
PN US5744449-A.
XX
PD 28-APR-1998.
XX
PF 03-JUN-1996; 96US-0657163.
XX
PR 03-JUN-1996; 96US-0657163.
PR 10-MAY-1993; 93US-0058387.
PR 22-SEP-1994; 94US-0310340.
XX
PA (LIPP/) LIPPS B V.
PA (LIPP/) LIPPS F W.
XX
PI Lipps BV, Lipps FW;
XX
DR WPI; 1998-271108/24.
XX
PT Lethal Toxin Neutralising Factor peptide from opossum - can
PT neutralise venom(s) from all major families of poisonous snakes
XX
PS Claim 1; Column 11; 11pp; English.
XX
CC This sequence represents the peptide of the invention. It is a Lethal
CC Toxin Neutralising Factor (LTNF) moiety from a 68 kDa anti-haemorrhagic
CC protein derived from an opossum. The peptide can be used in a method for
CC treating a victim of envenomation from a poisonous snake, preferably a
CC poisonous snake from the family of Elapidae, Viperidae or sea snake.
CC It is useful for the treatment of snake bites, sepsis, allergies caused
CC by the environment and treatment of bee or scorpion stings or toxicities
CC caused by plant or bacterial toxins. The peptide can also be used in
CC histamine reaction treatment. The peptide can be used in envenomation
CC treatment for a variety of snakes without prior identification of the
CC snake. Being short it can be synthetically prepared rather than the
CC current production in horses, where some people can show hypersensitivity
CC to horse proteins.
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 84; DB 19; Length 15;
Best Local Similarity 100.0%; Pred. No. 8.7e-07;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LKAMDPTPPLWIKTE 15
||||||||||||||||
Db 1 LKAMDPTPPLWIKTE 15

RESULT 3
AAW53843
ID AAW53843 standard; peptide; 10 AA.
XX
AC AAW53843;
XX
DT 08-JUL-1998 (first entry)
XX
DE N-terminus of opossum LTNF.
XX
KW LTNF; lethal toxin neutralising factor; opossum; envenomation; therapy;
KW anti-haemorrhagic protein; Elapidae; Viperidae; sea snake; snake bite;
KW sepsis; allergy; bee sting; scorpion sting; plant toxin; bacterial toxin;
KW histamine reaction treatment.
XX
OS Didelphis virginiana.
XX
PN US5744449-A.
XX
PD 28-APR-1998.
XX
PF 03-JUN-1996; 96US-0657163.
XX
PR 03-JUN-1996; 96US-0657163.
PR 10-MAY-1993; 93US-0058387.
PR 22-SEP-1994; 94US-0310340.
XX
PA (LIPP/) LIPPS B V.
PA (LIPP/) LIPPS F W.
XX
PI Lipps BV, Lipps FW;
XX
DR WPI; 1998-271108/24.
XX
PT Lethal Toxin Neutralising Factor peptide from opossum - can
PT neutralise venom(s) from all major families of poisonous snakes
XX
PS Claim 7; Column 11; 11pp; English.
XX
CC This sequence represents the peptide of the invention. It is a Lethal
CC Toxin Neutralising Factor (LTNF) moiety from a 68 kDa anti-haemorrhagic
CC protein derived from an opossum. The peptide can be used in a method for
CC treating a victim of envenomation from a poisonous snake, preferably a
CC poisonous snake from the family of Elapidae, Viperidae or sea snake.
CC It is useful for the treatment of snake bites, sepsis, allergies caused
CC by the environment and treatment of bee or scorpion stings or toxicities
CC caused by plant or bacterial toxins. The peptide can also be used in
CC histamine reaction treatment. The peptide can be used in envenomation
CC treatment for a variety of snakes without prior identification of the
CC snake. Being short it can be synthetically prepared rather than the
CC current production in horses, where some people can show hypersensitivity
CC to horse proteins.
XX
SQ Sequence 10 AA;

```
  Query Match             64.3%;  Score 54;  DB 19;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 0.033;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 LKAMDPTPPL 10
              ||||||||||
Db          1 LKAMDPTPPL 10


RESULT 4
ABG18144
ID   ABG18144 standard; Protein; 303 AA.
XX
AC   ABG18144;
XX
DT   18-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #18135.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS82331.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity  -
XX
PS   Claim 20; SEQ ID No 48503; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   303 AA;

  Query Match             56.0%;  Score 47;  DB 22;  Length 303;
  Best Local Similarity   42.9%;  Pred. No. 15;
  Matches    6;  Conservative    4;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          2 KAMDPTPPLWIKTE 15
              :| || || |:: :
Db         39 EASDPVPPYWVRLQ 52


RESULT 5
AAY74718
ID   AAY74718 standard; Protein; 267 AA.
XX
AC   AAY74718;
XX
DT   21-MAR-2000  (first entry)
XX
DE   Neisseria meningitidis ORF 241 protein sequence SEQ ID NO:910.
XX
KW   Neisseria meningitidis; Neisseria gonorrheae; antigen; vaccine;
KW   antigenic; diagnosis; immunogenic; infection; meningitis; septicaemia;
KW   antibacterial; gene therapy.
XX
OS   Neisseria meningitidis.
XX
PN   WO9957280-A2.
XX
PD   11-NOV-1999.
XX
PF   30-APR-1999;   99WO-US09346.
XX
PR   01-MAY-1998;   98US-0083758.
PR   31-JUL-1998;   98US-0094869.
PR   02-SEP-1998;   98US-0098994.
PR   02-SEP-1998;   98US-0099062.
PR   09-OCT-1998;   98US-0103749.
PR   09-OCT-1998;   98US-0103794.
PR   09-OCT-1998;   98US-0103796.
PR   25-FEB-1999;   99US-0121528.
XX
PA   (CHIR ) CHIRON CORP.
PA   (GENO-) INST GENOMIC RES.
XX
PI   Fraser C,  Galeotti C,  Grandi G,  Hickey E,  Masignani V,  Mora M;
PI   Petersen J,  Pizza M,  Rappuoli R,  Ratti G,  Scalato E,  Scarselli M;
PI   Tettelin H,  Venter JC;
XX
DR   WPI; 2000-062150/05.
DR   N-PSDB; AAZ53480.
XX
PT   Novel Neisserial polypeptides predicted to be useful antigens for
PT   vaccines and diagnostics  -
XX
PS   Claim 2; Page 553; 1453pp; English.
XX
CC   AAZ53015 to AAZ54536, AAZ54577 to AAZ54615, and AAY74253 to AAY75941
CC   represent novel Neisseria meningitis and N. gonorrheae polynucleotides
CC   and polypeptides. AAZ54537 to AAZ54576 and AAZ54616 to AAZ55473 represent
CC   PCR primers used in the exemplification of the present invention. The
CC   polypeptides, the polynucleotides, antibodies and compositions of
CC   the invention can be used as vaccines, as diagnostic reagents, and as
CC   immunogenic compositions. The polypeptides can be used in the
CC   manufacture of medicaments for treating or preventing infection due to
CC   Neisserial bacteria (e.g. meningitis and septicaemia), to detect the
CC   presence of Neisseria bacteria, or to raise antibodies. They may also
CC   be used to screen for agonists or antagonists, which may themselves
CC   have use as antibacterial agents. The polynucleotides of the invention
CC   may also be used in gene therapy protocols.
XX
SQ   Sequence   267 AA;

  Query Match             54.8%;  Score 46;  DB 21;  Length 267;
  Best Local Similarity   58.3%;  Pred. No. 19;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy          3 AMDPTPPLWIKT 14
              | . |||| |::|
Db          9 AKHPTPPTWLQT 20


RESULT 6
AAY74721
ID   AAY74721 standard; Protein; 267 AA.
XX
AC   AAY74721;
XX
DT   21-MAR-2000  (first entry)
XX
DE   Neisseria meningitidis ORF 241 protein sequence SEQ ID NO:916.
XX
KW   Neisseria meningitidis; Neisseria gonorrheae; antigen; vaccine;
KW   antigenic; diagnosis; immunogenic; infection; meningitis; septicaemia;
KW   antibacterial; gene therapy.
XX
OS   Neisseria meningitidis.
XX
PN   WO9957280-A2.
XX
PD   11-NOV-1999.
XX
PF   30-APR-1999;   99WO-US09346.
XX
PR   01-MAY-1998;   98US-0083758.
PR   31-JUL-1998;   98US-0094869.
PR   02-SEP-1998;   98US-0098994.
PR   02-SEP-1998;   98US-0099062.
PR   09-OCT-1998;   98US-0103749.
PR   09-OCT-1998;   98US-0103794.
PR   09-OCT-1998;   98US-0103796.
PR   25-FEB-1999;   99US-0121528.
XX
PA   (CHIR ) CHIRON CORP.
PA   (GENO-) INST GENOMIC RES.
XX
PI   Fraser C,  Galeotti C,  Grandi G,  Hickey E,  Masignani V,  Mora M;
PI   Petersen J,  Pizza M,  Rappuoli R,  Ratti G,  Scalato E,  Scarselli M;
PI   Tettelin H,  Venter JC;
XX
DR   WPI; 2000-062150/05.
DR   N-PSDB; AAZ53483.
XX
PT   Novel Neisserial polypeptides predicted to be useful antigens for
PT   vaccines and diagnostics  -
XX
PS   Claim 2; Page 555; 1453pp; English.
XX
CC   AAZ53015 to AAZ54536, AAZ54577 to AAZ54615, and AAY74253 to AAY75941
CC   represent novel Neisseria meningitis and N. gonorrheae polynucleotides
CC   and polypeptides. AAZ54537 to AAZ54576 and AAZ54616 to AAZ55473 represent
CC   PCR primers used in the exemplification of the present invention. The
CC   polypeptides, the polynucleotides, antibodies and compositions of
CC   the invention can be used as vaccines, as diagnostic reagents, and as
CC   immunogenic compositions. The polypeptides can be used in the
CC   manufacture of medicaments for treating or preventing infection due to
CC   Neisserial bacteria (e.g. meningitis and septicaemia), to detect the
CC   presence of Neisseria bacteria, or to raise antibodies. They may also
CC   be used to screen for agonists or antagonists, which may themselves
CC   have use as antibacterial agents. The polynucleotides of the invention
CC   may also be used in gene therapy protocols.
XX
SQ   Sequence   267 AA;

  Query Match           54.8%;  Score 46;  DB 21;  Length 267;
  Best Local Similarity   58.3%;  Pred. No. 19;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          3 AMDPTPPLWIKT 14
              |  |||| |::|
Db          9 AKHPTPPTWLQT 20


RESULT 7
ABB59797
ID   ABB59797 standard; Protein; 729 AA.
XX
AC   ABB59797;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Drosophila melanogaster polypeptide SEQ ID NO 6183.
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical.
XX
OS   Drosophila melanogaster.
XX
PN   WO200171042-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US09231.
XX
PR   23-MAR-2000; 2000US-191637P.
PR   11-JUL-2000; 2000US-0614150.
XX
PA   (PEKE ) PE CORP NY.
XX
PI   Venter JC,  Adams M,  Li PWD,  Myers EW;
XX
DR   WPI; 2001-656860/75.
DR   N-PSDB; ABL03900.
XX
PT   New isolated nucleic acid detection reagent for detecting 1000 or more
PT   genes from Drosophila and for elucidating cell signalling and cell-cell
PT   interactions -
XX
PS   Disclosure; SEQ ID NO 6183; 21pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated nucleic acid detection reagent
CC   capable of detecting 1000 or more genes from Drosophila. The invention is
CC   useful in developmental biology and in elucidating cell signalling and
CC   cell-cell interactions in higher eukaryotes for the development of
CC   insecticides, therapeutics and pharmaceutical drugs. The invention
CC   discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC   sequences (ABL01840-ABL16175) and the encoded proteins
CC   (ABB57737-ABB72072).
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   729 AA;

  Query Match           54.8%;  Score 46;  DB 22;  Length 729;
  Best Local Similarity   57.1%;  Pred. No. 55;
  Matches    8;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          1 LKAMDPTPPLWIKT 14
              ||| : | |||: |
Db        689 LKAQNSTSPLWLNT 702


RESULT 8
AAR56496
ID   AAR56496 standard; Protein; 1189 AA.
XX
AC   AAR56496;
XX
DT   23-MAR-1995  (first entry)
XX
DE   TATA-binding protein-associated factor dTAFI50.
```

```
XX
KW   TATA-binding protein associated factor; dTAFI50; screening;
KW   diagnostic; therapeutic; gene transcription regulation.
XX
OS   Drosophila.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 923
FT                   /note= "Val or Leu"
FT   Misc-difference 1106
FT                   /note= "Arg, Pro or His"
FT   Misc-difference 1172
FT                   /note= "STOP"
FT   Misc-difference 1176
FT                   /note= "STOP"
XX
PN   WO9417087-A.
XX
PD   04-AUG-1994.
XX
PF   28-JAN-1994;   94WO-US01114.
XX
PR   28-JAN-1993;   93US-0013412.
PR   30-JUN-1993;   93US-0087119.
XX
PA   (REGC ) UNIV CALIFORNIA.
XX
PI   Comai L,  Dynlact BD,  Hoey T,  Ruppert S,  Tanese N;
PI    Tjian R,  Wang E,  Weinzierl ROJ;
XX
DR   WPI; 1994-264019/32.
DR   N-PSDB; AAQ70733.
XX
PT   TATA-binding protein associated protein factors - and
PT   corresponding nucleotide sequence and deriv. antibodies, useful
PT   in screening, diagnostics and therapeutics
XX
PS   Disclosure; Page 156; 180pp; English.
XX
CC   The TATA-binding protein associated factor hTAFI50 (including
CC   specific antibodies and fusion products) are used in drug screening,
CC   diagnostics and therapeutics.  They are used in the development of
CC   specific biochemical assays for screening compounds that agonise or
CC   antagonise selected transcription factors involved in regulating
CC   gene expression associated with human pathology.
XX
SQ   Sequence   1189 AA;

  Query Match             54.8%;  Score 46;  DB 15;  Length 1189;
  Best Local Similarity   53.3%;  Pred. No. 92;
  Matches    8;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          1 LKAMDPTPPLWIKTE 15
              | ||| :| |||: :
Db        589 LSAMDDSPVLWIRLD 603


RESULT 9
AAW06086
ID   AAW06086 standard; Protein; 1213 AA.
XX
AC   AAW06086;
XX
DT   27-JAN-1997  (first entry)
XX
DE   Drosophila TATA-binding protein associated factor dTAFII150 protein.
XX
KW   Drosophila; TATA-binding protein; TBP associated factor; TFIID;
KW   RNA polymerase II; transcription; messenger RNA; nuclear fraction;
KW   holoenzyme; lambda-gt11; expression library.
XX
OS   Drosophila melanogaster.
XX
PN   US5534410-A.
XX
PD   09-JUL-1996.
XX
PF   28-JAN-1993;   93US-0013412.
XX
PR   28-JAN-1994;   94US-0188582.
PR   28-JAN-1993;   93US-0013412.
PR   30-JUN-1993;   93US-0087119.
XX
PA   (REGC ) UNIV CALIFORNIA.
XX
PI   Comai L,  Dynlacht BD,  Hoey T,  Ruppert S,  Tanese N;
PI   Tjian R,  Wang E, Weinzierl ROJ;
XX
DR   WPI; 1996-333245/33.
DR   N-PSDB; AAT42219.
XX
PT   Screen for cpds. that bind human TATA-binding protein associated
PT   factor - by testing ability to bind to polypeptide fragments of the
PT   factor, useful as (ant)agonists of transcription factors involved in
PT   disease.
XX
PS   Examples; Column 123-132; 86pp; English.
XX
CC   This is the amino acid sequence of the Drosophila TATA-binding protein
CC   (TBP) associated factor (TAF) designated TAFII60. The protein is a
CC   component of the TFIID fraction required for reconstituting RNA
CC   polymerase II in vitro transcription activity.  The encoded protein
CC   has an estimated mol. wt. of 60 kD by SDS-PAGE.
CC   The invention relates to purified proteins involved in transcription
CC   by RNA polymerase II, the RNA polymerase which transcribes messenger
CC   RNA. RNA polymerase II transcription proceeds in vitro upon addition
CC   of several nuclear fractions designated TFIIA, B, D, E, F, H, I and J
CC   to RNA polymerase II holoenzyme. Fraction TFIID has been shown to
CC   contains a TBP and other TAFs. Purification of TFIID and separation of
CC   its components reveals 7 proteins ranging in size from 30-250 kD.
CC   Serum raised against the TFIID fraction allowed cloning of the corresp.
CC   genes from lambda-gt11 expression libraries.
XX
SQ   Sequence   1213 AA;

  Query Match             54.8%;  Score 46;  DB 17;  Length 1213;
  Best Local Similarity   53.3%;  Pred. No. 94;
  Matches    8;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          1 LKAMDPTPPLWIKTE 15
              | ||| :| |||: :
Db        620 LSAMDDSPVLWIRLD 634


RESULT 10
AAW25029
ID   AAW25029 standard; Protein; 1213 AA.
XX
AC   AAW25029;
XX
DT   08-OCT-1997  (first entry)
XX
DE   TATA-binding protein associated factor, dTAFII150.
XX
KW   TATA-binding protein associated factor; TAF; nuclear protein;
KW   RNA polymerase transcription; TATA-binding protein; TBP;
KW   initiation.
XX
OS   Drosophila sp.
XX
PN   US5637686-A.
XX
PD   10-JUN-1997.
XX
PF   28-JAN-1993;   93US-0013412.
XX
```

```
PR   28-JAN-1994;   94US-0188582.
PR   28-JAN-1993;   93US-0013412.
PR   30-JUN-1993;   93US-0087119.
PR   09-MAY-1996;   96US-0646715.
XX
PA   (REGC ) UNIV CALIFORNIA.
XX
PI   Comai L,  Dynlact BD,  Hoey T,  Ruppert S,  Tanese N;
PI   Tjian R,  Wang E, Weinzierl ROJ;
XX
DR   WPI; 1997-319113/29.
DR   N-PSDB; AAT79605.
XX
PT   Nucleic acids encoding human TATA-binding protein associated factor
PT   (TAF) peptide(s) - for production of recombinant peptide(s), used
PT   for modulating transcription of TAFs
XX
PS   Example 1; Column 131-138; 86pp; English.
XX
CC   AAW25029 represents TATA-binding protein associated factor (TAF)
CC   polypeptide, dTAFII150 (mol. weight 150kD). TAF peptides derived
CC   from dTAFII30 alpha, dTAFII30 beta, dTAFII40, dTAFII60, dTAFII80,
CC   dTAFII110, dTAFII150, and dTAFII250, their human equivalents and
CC   nucleic acids encoding them, are used to modulate transcription,
CC   including transcription initiation. TAFS are nuclear proteins involved
CC   in RNA polymerase I, II and III transcription. The peptides act by
CC   binding to a different TAF, an activator, or TBP (TATA-binding protein)
CC   or competitively inhibiting association of a TAF domain with another
CC   compound, typically a protein like TBP or another TAF, an activator,
CC   or DNA.
XX
SQ   Sequence   1213 AA;

  Query Match             54.8%;  Score 46;  DB 18;  Length 1213;
  Best Local Similarity   53.3%;  Pred. No. 94;
  Matches    8;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          1 LKAMDPTPPLWIKTE 15
              | ||| :| |||: :
Db        620 LSAMDDSPVLWIRLD 634


RESULT 11
ABB62618
ID   ABB62618 standard; Protein; 1219 AA.
XX
AC   ABB62618;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Drosophila melanogaster polypeptide SEQ ID NO 14646.
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical.
XX
OS   Drosophila melanogaster.
XX
PN   WO200171042-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US09231.
XX
PR   23-MAR-2000; 2000US-191637P.
PR   11-JUL-2000; 2000US-0614150.
XX
PA   (PEKE ) PE CORP NY.
XX
PI   Venter JC,  Adams M,  Li PWD,  Myers EW;
XX
DR   WPI; 2001-656860/75.
DR   N-PSDB; ABL06721.
XX
PT   New isolated nucleic acid detection reagent for detecting 1000 or more
PT   genes from Drosophila and for elucidating cell signalling and cell-cell
PT   interactions -
XX
PS   Disclosure; SEQ ID NO 14646; 21pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated nucleic acid detection reagent
CC   capable of detecting 1000 or more genes from Drosophila. The invention is
CC   useful in developmental biology and in elucidating cell signalling and
CC   cell-cell interactions in higher eukaryotes for the development of
CC   insecticides, therapeutics and pharmaceutical drugs. The invention
CC   discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC   sequences (ABL01840-ABL16175) and the encoded proteins
CC   (ABB57737-ABB72072).
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   1219 AA;

  Query Match             54.8%;  Score 46;  DB 22;  Length 1219;
  Best Local Similarity   53.3%;  Pred. No. 95;
  Matches    8;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          1 LKAMDPTPPLWIKTE 15
              | ||| :| |||: :
Db        618 LSAMDDSPVLWIRLD 632


RESULT 12
AAY74720
ID   AAY74720 standard; Protein; 267 AA.
XX
AC   AAY74720;
XX
DT   21-MAR-2000  (first entry)
XX
DE   Neisseria meningitidis ORF 241 protein sequence SEQ ID NO:914.
XX
KW   Neisseria meningitidis; Neisseria gonorrheae; antigen; vaccine;
KW   antigenic; diagnosis; immunogenic; infection; meningitis; septicaemia;
KW   antibacterial; gene therapy.
XX
OS   Neisseria meningitidis.
XX
PN   WO9957280-A2.
XX
PD   11-NOV-1999.
XX
PF   30-APR-1999;   99WO-US09346.
XX
PR   01-MAY-1998;   98US-0083758.
PR   31-JUL-1998;   98US-0094869.
PR   02-SEP-1998;   98US-0098994.
PR   02-SEP-1998;   98US-0099062.
PR   09-OCT-1998;   98US-0103749.
PR   09-OCT-1998;   98US-0103794.
PR   09-OCT-1998;   98US-0103796.
PR   25-FEB-1999;   99US-0121528.
XX
PA   (CHIR ) CHIRON CORP.
PA   (GENO-) INST GENOMIC RES.
XX
PI   Fraser C,  Galeotti C,  Grandi G,  Hickey E,  Masignani V,  Mora M;
PI   Petersen J,  Pizza M,  Rappuoli R,  Ratti G,  Scalato E,  Scarselli M;
PI   Tettelin H,  Venter JC;
XX
DR   WPI; 2000-062150/05.
DR   N-PSDB; AAZ53482.
XX
PT   Novel Neisserial polypeptides predicted to be useful antigens for
PT   vaccines and diagnostics -
XX
```

```
PS   Claim 2; Page 554; 1453pp; English.
XX
CC   AAZ53015 to AAZ54536, AAZ54577 to AAZ54615, and AAY74253 to AAY75941
CC   represent novel Neisseria meningitis and N. gonorrheae polynucleotides
CC   and polypeptides. AAZ54537 to AAZ54576 and AAZ54616 to AAZ55473 represent
CC   PCR primers used in the exemplification of the present invention. The
CC   polypeptides, the polynucleotides, antibodies and compositions of
CC   the invention can be used as vaccines, as diagnostic reagents, and as
CC   immunogenic compositions. The polypeptides can be used in the
CC   manufacture of medicaments for treating or preventing infection due to
CC   Neisserial bacteria (e.g. meningitis and septicaemia), to detect the
CC   presence of Neisseria bacteria, or to raise antibodies. They may also
CC   be used to screen for agonists or antagonists, which may themselves
CC   have use as antibacterial agents. The polynucleotides of the invention
CC   may also be used in gene therapy protocols.
XX
SQ   Sequence   267 AA;

  Query Match             53.6%;  Score 45;  DB 21;  Length 267;
  Best Local Similarity   58.3%;  Pred. No. 28;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          3 AMDPTPPLWIKT 14
              |  |||| |::|
Db          9 ANPPTPPTWLQT 20


RESULT 13
ABB42105
ID   ABB42105 standard; Peptide; 37 AA.
XX
AC   ABB42105;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #9611 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00669.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human fetal liver -
XX
PS   Claim 27; SEQ ID NO 34740; 639pp + sequence listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for
CC   measuring human gene expression in a sample derived from human foetal
CC   liver. The single exon nucleic acid probes may be used for predicting,
CC   measuring and displaying gene expression in samples derived from human
CC   fetal liver. The present sequence is a peptide encoded by a single exon
CC   nucleic acid probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   37 AA;

  Query Match             52.4%;  Score 44;  DB 22;  Length 37;
  Best Local Similarity   46.2%;  Pred. No. 5;
  Matches    6;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 KAMDPTPPLWIKT 14
              |:| | || |:::
Db          5 KSMGPAPPRWMRS 17


RESULT 14
AAM62985
ID   AAM62985 standard; Protein; 37 AA.
XX
AC   AAM62985;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe encoded protein SEQ ID NO: 35090.
XX
KW   Human; brain expressed exon; gene expression analysis; probe;
KW   microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
KW   epilepsy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00667.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   brains -
XX
PS   Example 4; SEQ ID NO: 35090; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention.
XX
SQ   Sequence   37 AA;

  Query Match             52.4%;  Score 44;  DB 22;  Length 37;
  Best Local Similarity   46.2%;  Pred. No. 5;
  Matches    6;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 KAMDPTPPLWIKT 14
              |:| | || |:::
Db          5 KSMGPAPPRWMRS 17
```

```
RESULT 15
AAM75798
ID   AAM75798 standard; Protein; 37 AA.
XX
AC   AAM75798;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human bone marrow expressed probe encoded protein SEQ ID NO: 36104.
XX
KW   Human; bone marrow expressed exon; gene expression analysis; probe;
KW   microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS   Homo sapiens.
XX
PN   WO200157276-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00668.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488900/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human bone marrow -
XX
PS   Example 4; SEQ ID NO: 36104; 658pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   bone marrow. They can be used to measure gene expression in bone marrow
CC   samples, which may enable the improved diagnosis and treatment of cancers
CC   such as lymphoma, leukaemia and myeloma. The present sequence is a
CC   protein encoded by one of the probes of the invention.
XX
SQ   Sequence   37 AA;

  Query Match             52.4%;  Score 44;  DB 22;  Length 37;
  Best Local Similarity   46.2%;  Pred. No. 5;
  Matches    6;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 KAMDPTPPLWIKT 14
              |:| | || |::: 
Db          5 KSMGPAPPRWMRS 17


Search completed: June 27, 2003, 18:01:23
Job time : 38 secs
```